Topical therapy with clobetasol propionate 0.025% for various dermatological conditions

Vishwanath Prem Raj, Nitin Pandit Tayade, Chandrashekhar V. Kiswe, Nimesh Surendrakumar Shah, Suneel Singh Sengar, Indira Pavan, Sanjay Ramanbhai Gamit, Mohit Bansal, Sachin Kumar, Ankit Yadav


Topical corticosteroids (TC) are the most commonly prescribed medications for the treatment of several dermatoses. Owing to their potent effect of relieving symptoms, these drugs are indicated for the use of inflammatory and pruritic presentations of dermatologic conditions. Clobetasol propionate (CP) is the most common TC used to treat itching, redness, and swelling caused by some skin conditions. It possesses anti-inflammatory, antipruritic, and vasoconstrictive properties. To exert its effect, CP binds to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor-mediated gene expression, thus resulting in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. This case series discusses the efficacy, safety, and clinical experience of using CP 0.025% cream for the treatment of different dermatologic conditions.


Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Full Text:



Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. Available at: Accessed on 18 November 2021.

Rathi SK, D’Souza1 P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251-59.

Pels R, Sterry W, Lademann J. Clobetasol propionate--where, when, why? Drugs Today (Barc). 2008;44(7):547-57.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Meglio PDVillanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354.

Sidgiddi S, Naqvi SMH, Shenoy M. Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: Phase-2a, randomized 3-arm study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.